whites and economically active age group), except for the treatment result (the cure rate for coinfecting patients is predominant, Which does not reflect the country profile, however, the death rate remains an alarming situation, as well as the hospitalisation rate for associated complications).

Conclusion The interaction of diseases requires the need for coordinated work developed by TB and HIV/AIDS programs to reduce the burden of both diseases and promote more favourable outcomes.

P3.81 LATIN AMERICA PROFICIENCY TESTING PROGRAM FOR DIAGNOSIS AND ANTIMICROBIAL SUSCEPTIBILITY OF *NEISSERIA GONORRHOEA*

¹P Galarza, ¹R Gianecini, ¹C Oviedo, ¹K Silva, ²P Ramon Pardo, ²M Ghidinelli, ²M Galas and ³NGQCP Participants. ¹Instituto Nacional de Enfermedades Infecciosas (INEI) – ANLIS. Ciudad Autónoma de Buenos Aires, Argentina; ²Pan-American Health Organisation (PAHO). World Health Organisation (WHO); ³Latin American Quality Control Comparison Program in Diagnostic and Antimicrobial Susceptibility Testing for *Neisseria gonorrhoeae*

10.1136/sextrans-2017-053264.316

Introduction Since 2013 an ongoing international inter-laboratory quality control program (NGQCP) has analysed the capability of 16 national reference laboratories to diagnose and perform antimicrobial susceptibility testing (AST) for *Neisseria gonorrhoeae* in Latin America. The program is supported by PAHO/WHO for the GASP-RELAVRA network and coordinated by the Sexually Transmitted Disease Reference Laboratory (LC) - INEI from Argentina. Results of the 2016 fourth round of the NGQCP are presented.

Methods A panel with 5 isolates belong to *Neisseriaceae* family, is envoyed once by year. A questionnaire is attached to collect information from each codified laboratory (lab). The 2008 WHO panel and ATCC 49226 reference strains were distributed. NGQCP evaluate: presumptive and confirmatory identification and, AST by disk diffusion and Minimum inhibitory concentrations (MICs) determination by either agar dilution or Etest methods. MIC interpretations were based on the criteria of the Clinical Laboratory Standards Institute (CLSI).

Results Fifteen labs recovered isolates. Complete conventional presumptive and confirmatory identification was made by 73% and 87% of labs, respectively. Only 3 labs introduced a different confirmatory methodology. The 97.3% (72/74) of diagnostics were included in the category genus and species correct. Three (3/15) labs not realised β -lactamase detection. Disk diffusion assessment showed 31 minor, 2 major and 3 very major discrepancies. The overall agreement of MIC results (MICs $\pm$ 1 log₂ dilutions) between 8 labs, including the LC, compared to the modal MICs was 90% (277/307). Percentage agreements by antibiotics was: penicillin 83% (49/59); tetracycline 89% (64/72); ciprofloxacin 93% (53/57); ceftriaxone 90% (53/59); cefixime 88% (7/8) and azithromycin 98% (51/52)

Conclusion NGQCP is an essential pillar for an effective surveillance program in order to ensure that their data are reliable. We expect more labs in the Region realise MIC determination by agar dilution methods and improve level of concordance for AST.

P3.82 AN UPWARD TREND IN OCULAR SYPHILIS CASES IN BRITISH COLUMBIA, CANADA, 2013–2016: A DESCRIPTIVE ANALYSIS

¹G Shumilak, ^{2,3}J Wong, ²B Arnold, ^{2,3}M Gilbert, ²C Lukac, ²S Makaroff, ²C Montgomery, ^{2,4}D Moore, ²C Prescott, ^{1,2}T Grennan. ¹Division of Infectious Diseases, University of British Columbia, Vancouver, Canada; ²BC Centre for Disease Control, Vancouver, Canada; ³School of Population and Public Health, University of British Columbia, Vancouver, Canada; ⁴BC Centre for Excellence in HIV/AIDS, Vancouver, Canada

10.1136/sextrans-2017-053264.317

Introduction HIV-positive individuals are generally considered higher risk for early and more serious neurologic complications related to syphilis. In 2014–2015, clusters of ocular syphilis cases were reported in the US. Simultaneously, the Canadian province of British Columbia (BC) saw a dramatic rise in infectious syphilis cases by 40%. Here, we describe ocular syphilis cases diagnosed in BC.

Methods All neurosyphilis cases diagnosed in BC since 2013 were reviewed to identify ocular cases. Ocular syphilis was defined as having signs/symptoms of ocular disease (e.g. uveitis, blurred vision) and syphilis of any stage, as defined by the Centres for Disease Control and Prevention.

Results Between January 1st, 2013 and October 31st, 2016, 35 cases of ocular syphilis were recorded in BC. Most were male (32/35; 91.4%) and identified as white (20/35; 57.1%). The mean age was 49.7 years. A majority (18/35; 51.4%) were living with HIV. The most frequent ophthalmologic diagnoses were uveitis (41.9%), optic neuritis (12.9%), and retinitis (9.7%). Twenty-three cases had lumbar puncture data available: 13 (56.5%) had elevated cerebrospinal fluid (CSF) protein, 15 (65.2%) had elevated CSF cell count, and 6 (26.1%) had positive CSF VDRL. As a proportion of all syphilis cases, ocular syphilis accounted for 0.80% of all cases during the 2013–2015 period, versus 1.54% for 2016 ($p=0.05$). Stratified by HIV serostatus, there was a significant increase in the proportion of ocular syphilis cases in those living with HIV between the 2013–2015 and 2016 time periods (1.17% vs. 3.21%, $p=0.03$).

Conclusion Paralleling trends observed in some US jurisdictions, BC is experiencing an increase in ocular syphilis cases, and an increasing proportion of syphilis cases in those living with HIV are being diagnosed with ocular findings. These results further highlight the importance of continuing efforts to respond to the syphilis epidemic, and focused screening for ocular symptoms, particularly in those at highest risk.

P3.83 ANTIMICROBIAL RESISTANCE OF *UREAPLASMA UREALYTICUM* AND *MYCOPLASMA HOMINIS* RESEARCHED AT A REFERENCE CENTRE IN SALVADOR, BAHIA

¹GC Souza, ²E Xavier-Souza, ²MS Timbó, ¹V Cunha, ^{1,3}AG Travassos. ¹Universidade do Estado da Bahia, Brazil; ²Universidade Federal da Bahia, Brazil; ³Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa (CEDAP), Brazil

10.1136/sextrans-2017-053264.318

Introduction: *Ureaplasma urealyticum* (UU) and *Mycoplasma hominis* (MH) are potentially pathogenic organisms commonly found in the urogenital tract, with colonisation rates up to 80% and 40% worldwide, respectively. The aim of this study was to estimate antimicrobial resistance by UU and MH, and

identify the antimicrobial agents involved in bacterial resistance.

Methods A cross-sectional study, with data obtained retrospectively through medical records review. We analysed 140 patients whose women's endocervical samples and men's urine tested positive for MH and UU. The test used for the diagnosis and evaluation of antimicrobial resistance was the MYCO-FAST Screening Evolution 3 kit.

Results The majority of patients were female (90.7%), 57.9% of the patients had >29 years of age and 84.3% did not have a stable union. About 70.0% of the patients tested positive for UU, 3.0% for MH, and 27.0% for both. HIV co-infection was seen in 32.1% and HPV in 30.0%. Absence of current history of *Chlamydia trachomatis* was a protective factor for the acquisition of azithromycin resistance ($p=0.04$). As for the antimicrobials, doxycycline showed sensitivity rates higher than 96% for both infections, while azithromycin showed 86.8% of sensitivity for UU, but resistance of 75% for MH. Ciprofloxacin showed sensitivity rates lower than 15% for both infections, while less than 35% were strains sensible to ofloxacin. Erythromycin resistance rates ranged over 65% for the UU-MH coinfection, while over 90% of sample was sensible to tetracycline and clarithromycin resistance rates ranged from 7.1% for UU to 100% for MH.

Conclusion The use of ciprofloxacin and ofloxacin is highly debatable considering the high rates of total and intermediate resistance. In our population, doxycycline showed high efficiency and is therefore recommended for the treatment of UU and MH infections. Monitoring antimicrobial resistance is fundamental for the adequacy of the therapeutic recommendations.

P3.84 ESTIMATING THE ANTIBODY PREVALENCE OF HERPES SIMPLEX VIRUS TYPE 1 AMONG SELECT MIDDLE EAST AND NORTH AFRICA POPULATIONS

¹Gheyath Nasrallah, ²Soha Dargham, ¹Layla Mohammed, ²Laith Abu-Raddad. ¹Qatar University, Doha, Qatar; ²Weill Cornell Medicine-Qatar, Doha, Qatar

10.1136/sextrans-2017-053264.319

Introduction Evidence indicates a growing role for herpes simplex virus type-1 (HSV-1) as a sexually transmitted infection and as the etiological agent of genital herpes, but HSV-1 epidemiology in the Middle East and North Africa (MENA) remains poorly understood. We aimed to measure HSV-1 antibody prevalence among select MENA populations and to characterise the infection's age-distribution.

Methods Evidence indicates a growing role for herpes simplex virus type-1 (HSV-1) as a sexually transmitted infection and as the etiological agent of genital herpes, but HSV-1 epidemiology in the Middle East and North Africa (MENA) remains poorly understood. We aimed to measure HSV-1 antibody prevalence among select MENA populations and to characterise the infection's age-distribution.

Results Country-specific HSV-1 prevalence was estimated for 10 MENA national populations of male blood donors residing in Qatar. HSV-1 prevalence was estimated at 97.5% (95% confidence interval (CI) 95.3%–98.7%) among Egyptians, 92.6% (95% CI 87.2%–95.8%) among Yemenis, 90.7% (95% CI 84.5%–94.6%) among Sudanese, 88.5% (95% CI 83.9%–92.6%) among Syrians, 86.5% (95% CI 81.0%–90.5%) among

Jordanians, 82.3% (95% CI 78.2%–85.7%) among Qataris, 81.4% (95% CI 73.3%–87.5%) among Iranians, 81.4% (95% CI 73.4%–87.4%) among Lebanese, 80.5% (95% CI 74.2%–85.2%) among Palestinians, and 77.0% (95% CI 70.7%–82.3%) among Pakistanis. Age-specific HSV-1 prevalence was estimated among male blood donors from Egypt, the Fertile Crescent (Iraq, Jordan, Lebanon, Palestine and Syria) and Qatar. There was a trend of growing HSV-1 prevalence with age among the Fertile Crescent and Qatari nationals. HSV-1 prevalence increased from 70.0% (95% CI 56.3%–80.9%) for those aged <24 years up to 98.0% (95% CI 89.5%–99.7%) for those aged ≥55 years in the Fertile Crescent. Similar pattern was observed for Qatar, but for Egypt, prevalence was steadily above 90% for all age groups. Our results showed no significant association between sex and HSV-1 seropositivity.

Conclusion HSV-1 prevalence in MENA continues at high level, but for the majority of nationalities, at considerably lower levels than historical levels. The decline in prevalence is most pronounced among youth. As much as a third of those <30 years of age are reaching sexual debut with no protective antibodies against HSV-1 genital acquisition, and accordingly, are at risk of genital herpes.

P3.85 EVALUATION OF GENTAMICIN SUSCEPTIBILITY AND RESISTANCE PHENOTYPES OF *NEISSERIA GONORRHOEA* ISOLATES IN ARGENTINA

¹R Gianecini, ¹C Oviedo, ²GASSP-AR, ¹Galarza P. ¹Servicio de Enfermedades de Transmisión Sexual, Instituto Nacional de Enfermedades Infecciosas (INEI)-ANLIS "Dr. Carlos G. Malbrán", Ciudad Autónoma de Buenos Aires, Argentina.; ²Gonococcal Antimicrobial Susceptibility Surveillance Programme-Argentina (GASSP-AR)

10.1136/sextrans-2017-053264.320

Introduction The emergence of multidrug resistance in *N. gonorrhoeae* highlights the need to consider alternatives for future therapeutic use. Nowadays, the aminoglycoside gentamicin is considered a possible treatment option for gonorrhoea, particularly in dual therapy. Gentamicin has been used successfully for several years in the treatment of gonococcal urethritis in Malawi. However, treatment failures have been reported. In Argentina, *N. gonorrhoeae* isolates with multiple resistance profiles to different antimicrobials, including cefixime and ceftriaxone, have been detected. Therefore, the knowledge of the susceptibility to new antimicrobial options for gonorrhoea treatment is required. The aim of this study was to determine the susceptibility to gentamicin of *N. gonorrhoeae* isolates with different resistance profiles in 2013 and 2015.

Methods We studied 237 *N. gonorrhoeae* isolates obtained in 2013 and 2015 from the GASSP-AR. The MICs to penicillin, tetracycline, ciprofloxacin, cefixime, ceftriaxone, azithromycin and gentamicin were determined by the agar dilution test according to CLSI guidelines.

Results Gentamicin MICs ranged from 2 to 16 µg/ml. The MIC₅₀ and MIC₉₀ were 8 µg/ml. The rate of isolates with MIC 8 µg/ml was 67.1%, while 30.4% showed a MIC of 4 µg/ml. A 75.5% of the isolates included in this study showed resistance to one or more of the following antibiotics: penicillin (40.5%), tetracycline (30.4%), ciprofloxacin (59.9%), and 5.5% of the isolates showed decreased susceptibility to cefixime and ceftriaxone. A total of 15 resistance phenotypes